Emerging infectious disease laboratory and diagnostic preparedness to accelerate vaccine development

Christine C. Roberts

Clinical Laboratory Development, GeneOne Life Science, Inc., Blue Bell, PA, USA

ABSTRACT

Rapid vaccine development in response to an outbreak of a new emerging infectious disease (EID) is often targeted by public health agencies worldwide. This goal becomes more complicated when there are no standardized sets of viral and immunological assays, no accepted and well-characterized samples, standards or reagents, and no approved diagnostic tests for the EID pathogen. The diagnosis of infections is of critical importance to public health, but also in vaccine development in order to track incident infections during clinical trials, to differentiate natural infection responses from those that are vaccine-related and, if called for by study design, to exclude subjects with prior exposure from vaccine efficacy trials. Here we review emerging infectious disease biological standards development, vaccine clinical assay development and trial execution with the recent experiences of MERS-CoV and Zika virus as examples. There is great need to establish, in advance, the standardized reagents, sample panels, controls, and assays to support the rapid advancement of vaccine development efforts in response to EID outbreaks.

1. Introduction

The World Health Organization (WHO) has published a list of priority pathogens as those diseases with high morbidity and mortality or with strong epidemic potential. One of the clear gaps affecting both public health efforts and vaccine development programs for any of these pathogens is a lack of standardized reagents and methods to test for evidence of current or prior infection.

The need for fast and accurate diagnostic tests of infection in an outbreak situation is obvious: identify the source or epicenter so that appropriate health-care measures can be quickly instituted. Expanding that concept to the public health scale and attaining accurate infectious disease diagnoses allows for better understanding of the course and severity of an outbreak and aids decision-making for population-level countermeasure implementation.

The clinical assays with which the immune response and pathogen presence are measured in vaccine trials become part of the basis for licensure for all vaccine products. Because vaccines are tested in healthy populations through all phases of clinical development for immune response and/or pathogen presence, the methods selected to measure vaccine responses and endpoints are critical. While the identification of an immune correlate of protection for each new vaccine is highly desirable, it is not always attainable.

Here we will use our recent experiences with the Middle East Respiratory Syndrome coronavirus (MERS-CoV) and Zika virus (ZIKV) outbreaks and ensuing public health countermeasures for containment and vaccine development as examples of challenges faced during emerging infectious disease emergencies.

2. Biological reference materials and international standards

International reference materials and standards allow for a common set of reagents for a given pathogen to be available for the evaluation of the quality and consistency of clinical assays and to enable comparisons of assay data between studies. Such reference materials are established with rigorous evaluation and collaborations between multiple international laboratories and are typically assigned an international unit of measure at the completion of this process. The WHO also provides guidance for the development of individual secondary standards and their calibration to accepted international standards. This allows individual laboratories to maintain their own standards material that is traceable to the accepted international standard and not deplete the limited supply of the standard prematurely.

Efforts are currently underway to alleviate the international standards issue for MERS-CoV and ZIKV. Antibody and nucleic acid standards are in development for MERS-CoV, though the additional source material is being sought. In 2016, the WHO initiated a collaborative study effort for the development of ZIKV nucleic acid standards and, in 2017, made available a plasma sample panel through the US Food and Drug Administration (FDA) for evaluation of ZIKV immunoassays. The acquisition, characterization, and standardization of relevant pathogen strains such that the strains reflect what is currently in circulation and not just a prototype strain is also of concern. For EIDs, there can be an added complication...
for sharing such material if the disease is caused by a select agent requiring enhanced biosafety measures.

Many of the priority pathogens identified by WHO cause outbreaks that are difficult to predict and may be sporadic in nature. This complicates efforts to establish processes ahead of any outbreak to collect valuable acute and convalescent samples from individuals naturally infected by the respective viruses. There was, and still is, a lack of well-characterized human specimens from naturally infected MERS-CoV and ZIKV subjects that vaccine development groups could use to for assay development and, eventually, to establish a recognized set of standards that can be maintained over time. A potentially valuable source of relevant clinical samples is from ongoing epidemiological studies and clinical trials. Study designers should take care to incorporate proper language into the informed consents of participants to allow for the request of additional blood draws or sample collections and for the future use of their clinical samples for the purposes of standards and assay development. Such studies should also ensure that well-established chain-of-custody, sample handling, and sample storage procedures are in place to maintain the quality of these valuable specimens. A significant drawback of this approach is that often the samples may not have adequate characterization, may be of limited volume, and are proprietary to the study sponsors. It should also be taken into account that local laws or culture may be prohibitive to allowing specimens to be stored for future testing. A concerted effort and willingness among researchers and companies to share available clinical specimens would be a valuable step forward in EID preparedness.

Sample collection and handling are critical to the quality of the specimen and its ability to be used in assays, standards or controls. Even in vaccine studies conducted in developed nations, challenges to appropriate sample collection and handling can occur. We experienced an issue with the timing of specimen intake and handling at a biorepository used for our ZIKV trials which required immediate corrective action to de-risk samples collected at the remaining study time points and prior to initiation of a second study. Ensuring proper sample storage and shipping conditions, processing and aliquotting (with attention to contamination control), training of site and clinical research organization lab personnel, a clear chain of custody from collection to final application, intermediate quality control checks, and good data management is critical for collection of high quality samples that can be used in the future.

3. Vaccine clinical assays, reference reagents, international controls

In the case of EIDs, it can be difficult to predict what assays will be most useful or informative or will perhaps even provide an immune correlate of protection for a vaccine in early development. Little may be known about the basic virology or immunology of a new pathogen, though the need for developing vaccines and therapeutics is urgent. Some typical methods used as vaccine clinical assays are antibody-binding ELISAs, virus neutralization or bactericidal immunoassays, IFNγ-ELISpot or related cellular immune methodology using the target antigen or antigen-derived peptide pools, and detection of the pathogen through molecular or culture assays. Vaccine clinical assays measuring humoral and cellular immune responses developed early in a program will likely evolve as clinical development progresses or as the scientific knowledge base of the pathogen and relevant immunology broadens. As improvements in technology occur over time, early vaccine assays are often re-designed and bridged to assays with higher throughput, multiplexed detection, reduction of sample volumes, and automation to support testing of large numbers of specimens for late-stage clinical trials. Often, a variety of tests are evaluated early in the program and, based on the usefulness of the data, a down-selection occurs so that the most relevant few remain to support large Phase 3 clinical trials and licensure of the vaccine.

Accepted “gold standards” of immunoassays for use at the onset of an EID vaccine program are rare. Critical reagents, standards, and controls must be monitored for consistent sourcing, batch-to-batch variability and overall quality over time. The implementation of partnerships between governmental agencies, academic researchers and industry researchers to help secure these items for the identified priority pathogens before a need should arise is of great importance.

Reagents for newly emergent infectious diseases like MERS-CoV and ZIKV were not readily available from commercial vendors at the outset of vaccine development programs. As such, individual vaccine projects, including our own, had to rely on internally developed clinical assays to understand vaccine-related immune responses and to detect prior or current infections. Lack of standardization, however, can confound the interpretation of results from studies using different “home brew” assays across multiple laboratories such that study results cannot be directly compared in the absence of an accepted international standard or a proficiency panel of samples.

The vast experience of our DNA vaccine consortium allowed us to develop MERS-CoV- and ZIKV-specific tests such as ELISA, virus neutralization and ELISpot early in the development and pre-clinical testing of the respective plasmid DNA vaccine constructs. These assays were evaluated for consistent performance throughout pre-clinical studies and we were able to adapt their use to support our Phase 1 and Phase 1b/2a studies of GLS-5300 MERS-CoV vaccine and two Phase 1 GLS-5700 ZIKV vaccine clinical trials. As these vaccines move further into clinical development, work will need to continue to transition from our pre-clinical and early stage standards to well sourced and characterized human control reagents. The concern always remains, however, that the inability to use formally characterized and internationally accepted reagents and controls in early versions of vaccine clinical assays can result in maintenance challenges or regulatory hurdles later in the vaccine assays’ life cycle.

4. Diagnostics for emerging infectious diseases

Diagnostic assays are often the same style tests as those used in vaccine development, like antibody binding or molecular detection. However, their intended purpose is to accurately identify the infecting pathogen to enable health-care
professionals to initiate appropriate treatments and prevent further transmission of disease. Laboratory confirmation of a diagnosis for patient treatment must have sufficient clinical sensitivity and specificity to be useful, the criteria for which may be different than analytical sensitivity and specificity criteria specified by assays for use in vaccine trials.\textsuperscript{38–45} Very few tests have gained Emergency Use Authorization (EUA) from the FDA. There are 2 MERS-CoV diagnostic tests, both molecular-based viral RNA detection, which received EUA in 2013 in response to the recognition of the significant potential for a future public health emergency.\textsuperscript{46} For ZIKV, currently, 5 serological kits and 14 viral diagnostic kits have been granted EUA status.\textsuperscript{47} For ZIKV in particular, the response to the need for diagnostics was quite rapid with all EUA approvals rolling out over approximately 19 months from February 2016 through September 2017,\textsuperscript{48} shortly after the declaration of a public health emergency. Outside the US, the WHO’s Emergency Use Assessment and Listing procedures (EUALs) recognizes the need and can grant authorization for use of diagnostic kits in emergency situations.\textsuperscript{48} Although no MERS-CoV or ZIKV diagnostic kit, serological or viral, have been fully approved by the FDA to date, the FDA has worked collaboratively with developers to accelerate the approval process when outbreak conditions warrant.\textsuperscript{49} A number of published studies have evaluated EUA tests independently for relevant sensitivity and specificity performance or in comparative studies\textsuperscript{32,39,50–56} to aid in the selection of appropriate tests for the needs of epidemiological surveillance or public health diagnostics. Details outlining the relevant assay performance characteristics of each of the EUA-approved MERS-CoV and ZIKV assays can also be found on the FDA Medical Countermeasures webpage.\textsuperscript{46,57,58} In the instance of MERS, EUA diagnostics approvals were limited to use with select respiratory tract specimens from individuals with signs and symptoms of infection with MERS-CoV or with epidemiological risk factors (i.e., contact with probable or confirmed MERS-CoV patients or having a history of travel to locations where MERS-CoV cases occur) for the detection of MERS-CoV.\textsuperscript{46}

For ZIKV, a number of complications in diagnostic tests such as cross-reactivity of immunological assays and short window of viremia in various bodily fluids required establishment of an algorithm to confirm ZIKV infection. This confirmatory algorithm guidance for health-care providers was based on not only clinical symptoms, risk factors, and diagnostic test results,\textsuperscript{59,60} but also specifically for the use and interpretation of EUA diagnostic ZIKV IgM tests to indicate recent exposure with or without accompanying molecular ZIKV test results.\textsuperscript{59} The types of specimens and timing of collection of specimens that would provide the most reliable results was also a consideration in the ZIKV diagnosis algorithm.

5. Future preparedness for EIDs

The Coalition for Epidemic Preparedness Innovations (CEPI) and others are working to ensure that rapid response mechanisms are in place to address emerging infectious diseases.\textsuperscript{24,61,62} The CEPI coalition was launched in 2017 as an innovative concept to establish global partnerships between public, private, philanthropic and civic organizations with the goal of accelerating the development of vaccines against emerging infectious diseases and strengthening vaccine access capabilities before an outbreak situation is encountered. Funding to support development teams building the infrastructure necessary for rapid vaccine design, manufacture, and clinical assessment is being provided to help ensure that we are prepared for EID outbreaks that may occur.\textsuperscript{62} EID public health and countermeasure programs have unique challenges for diagnostic and vaccine clinical assay development purposes.\textsuperscript{2,39,41,63–71} There may be an incomplete understanding of the biology or epidemiology of a new pathogen, which can delay or confound the selection of a relevant vaccine target and the subsequent assay development to be used to evaluate the candidates. The field may suffer from a lack of available reagent sources or with inconsistency in quantity and quality of those available, especially early in the discovery and development process. The difficulty in obtaining or developing relevant human sample panels, reference materials and/or international standards for the evaluation of test methods add to the challenges to support assay performance from early vaccine development through licensure.\textsuperscript{10}

Although the speed at which the EID diagnostic or vaccine development field needs to move will be dependent upon the urgency of the pathogen outbreak and its impact on human life, scientific and quality principles must still apply when developing vaccine or diagnostic assays. Biological assay standardization is critical.\textsuperscript{2,10,17,71,72} At a minimum, the development of relevant biological assays with adequate sensitivity and specificity for the application should use biostatistics to establish and verify assay performance and to maintain the ability to produce stable and reproducible results over time to support diagnostic or vaccine program needs. The criteria for acceptability of any given test system will be dependent upon the nature of the pathogen, our understanding of the immunology to fight the pathogen (both of which may be poorly understood in an EID situation) and the assay platform. If assay performance consistency and quality are not demonstrated, the validity of clinical study results may be questioned. In the execution of vaccine clinical trials, assay methodology must be accurate, specific and robust with high-quality procedures in place for sample collection, processing, and storage to ensure success.\textsuperscript{25,26,36,37} The translatability of assay methodology is also important if the acceleration of vaccine development is dependent upon the use of animal challenge studies to establish efficacy or to help define a correlate of protection for an EID pathogen.

Efforts to prepare reagents, collect well-characterized samples, develop research materials, and international standards in advance for EIDs for whom alerts have already been raised, such as the WHO priority pathogens, through collaborative partnerships with governmental and philanthropic agencies along with academic and industry-based researchers will make us better suited to respond with speed to an outbreak.\textsuperscript{24,61,69,73} Assay standardization for these or any other newly emergent infectious disease will be challenging and take time to develop, collect and characterize quality
reagents, to achieve sufficient sources samples for the establishment of serological or molecular standards. The commitment of researchers and companies invested in the research, diagnosis, treatment, and prevention of EIDs to participate and contribute to organized efforts to create and validate internationally recognized standardized reagents, assays and controls for priority pathogens in advance of an emergency is imperative and the time to start building this framework is now.

Acknowledgments

The author would like to acknowledge Inovio Pharmaceuticals with whom we co-develop the GLS-5300 MERS-CoV and GLS-5700 Zika DNA vaccines, the David Weiner Laboratory at the Wistar Institute, Philadelphia, PA, the Gary Kobinger Laboratory at Laval University, Quebec, Canada and the GeneOne Life Science Teams: Clinical Research in Blue Bell, PA and Basic Research & Development in Seoul, Korea.

Disclosure of potential conflicts of interest

Author is an employee of GeneOne Life Science, Inc.

ORCID

Christine C. Roberts @ http://orcid.org/0000-0003-4359-7946

References

1. WHO. R&D Blueprint 2018 List of priority diseases. [accessed 2018 Sep 06]. https://www.who.int/blueprint/priority-diseases/en/
2. Madore DV, Meade BD, Rubin F, Deal C, Lynn F. Utilization of serologic assays to support efficacy of vaccines in nonclinical and clinical trials: meeting at the crossroads. Vaccine. 2010;28 (4539–4547). doi:10.1016/j.vaccine.2010.04.094.
3. Plotkin SA, Gilbert PB. Nomenclature for immune correlates of protection after vaccination. Clin Infect Dis. 2012;54(1615–1617). doi:10.1093/cid/cis238.
4. Muthunmani K, Falzarano D, Reusch EL, Tingley C, Flingai S, Villarreal DO, Wise M, Patel A, Izmirly A, Aljuaud A, et al. A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. Sci Transl Med. 2015;7 (301ra132). doi:10.1126/scitranslmed.aac7462.
5. Muthunmani K, Griffin BD, Agarwal S, Kudchodkar SB, Reusch EL, Choi H, Kraynak KA, Duperez EK, Keaton AA, Chung C, et al. In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunization with a prMEnv DNA vaccine. NPJ Vaccines. 2016;1(16021). doi:10.1038/npjvaccines.2016.21.
6. Griffin BD, Muthunmani K, Warner BM, Majer A, Hagan M, Audet J, Stein DR, Randanheera C, Racine T, De La Vega MA, et al. DNA vaccination protects mice against Zika virus-induced damage to the testes. Nat Commun. 2017;8(15743). doi:10.1038/s41467-017-00799-4.
7. Tebas P, Roberts CC, Muthunmani K, Reusch EL, Kudchodkar SB, Zaidi FI, White S, Khan AS, Racine T, Choi H, et al. Safety and Immunogenicity of an anti-zika virus DNA vaccine - preliminary report. N Engl J Med. 2017. doi:10.1056/NEJMoa1708120.
8. Kudchodkar SB, Choi H, Reusch EL, Esquivel R, Jin-Ah Kwon J, Jeong M, Maslow JN, Reed CC, White S, Kim JF, et al. Rapid response to an emerging infectious disease - Lessons learned from development of a synthetic DNA vaccine targeting Zika virus. Microbes Infect. 2018. doi:10.1016/j.micinf.2018.03.001.
9. Maslow JN. Vaccines for emerging infectious diseases: lessons from MERS coronavirus and Zika virus. Hum Vaccin Immunother. 2017;13 (2918–2930). doi:10.1080/21645515.2017.1358825.
10. Rampling T, Page M, Horby P. International biological reference preparations for epidemic infectious diseases. Emerg Infect Dis. 2015;21(205–211). doi:10.3201/eid2105.140820.
11. WHO. World Health. Organization manual for the preparation of secondary reference materials for in vitro diagnostic assays designed for infectious disease nucleic acid or antigen detection: calibration to WHO International Standards. World Health Organization Expert Committee on Biological Standardization; 2017 [accessed 2019 Apr 03]. https://www.who.int/bloodproducts/norms/SecStandManWHO/TRS_1004_web_Annex_6.pdf?ua=1.
12. WHO. Collaborative study to evaluate a candidate world health organization international standard for zika virus for nucleic acid amplification technique (NAT)-based assays. 2016 [accessed 2019 Apr 03]. http://www.who.int/iris/handle/10665/253051.
13. FDA provides new tools for the development and proper evaluation of tests for detecting Zika virus infection. <https://www.fda.gov/NewsEvents/Newsroom/Announcements/ucm521979.htm> (2017).
14. Beskow LM, Dombeck CB, Thompson CP, Watson-Ormond JK, Weinfurt KP. Informed consent for biobanking: consensus-based guidelines for adequate comprehension. Genet Med. 2015;17 (226–233). doi:10.1038/gim.2014.102.
15. Bossert S, Kahrs H, Heinemeyer U, Prokein J, Strech D. Participatory improvement of a template for informed consent documents in biobank research - study results and methodological reflections. BMC Med Ethics. 2017;18(78). doi:10.1186/s12910-017-0232-7.
16. Kinkerova J, Topolcan O. Biobanks in Horizon 2020: sustainability and attractive perspectives. Epma J. 2018;9(345–353). doi:10.1007/s13167-018-0153-7.
17. Lippi G, Cadamuro J. Novel opportunities for improving the quality of preanalytical phase. A glimpse to the future? J Med Biochem. 2017;36:293–300. doi:10.1515/jmb-2017-0028.
18. Lippi G, Baird GS, Banfi G, Bolenius K, Cadamuro J, Modena K, Church S, Cornes MP, Dacey A, Guillou A, Hoffmann G, et al. Improving secondary reference materials in vitro diagnostic assays for nucleic acid amplification in the preanalytical phase through innovation, on behalf of the European Federation for Clinical Chemistry and Laboratory Medicine (EFLM) Working Group for Preanalytical Phase (WG-PRE). Clin Chem Lab Med. 2017;55(489–500). doi:10.1515/cclm-2017-0107.
19. de Vries J, Bull SJ, Douombo O, Ibrahim M, Mercereau-Puijalon O, Kwiatkowski D, Parker M. Ethical issues in human genomics research in developing countries. BMC Med Ethics. 2011;12(5). doi:10.1186/1472-6939-12-5.
20. Staunton C, Moodley K. Challenges in biobank governance in Sub-Saharan Africa. BMC Med Ethics. 2013;14(35). doi:10.1186/1472-6939-14-35.
21. Tindana P, Molyneux CS, Bull S, Parker M. Ethical issues in the export, storage and reuse of human biological samples in biomedical research: perspectives of key stakeholders in Ghana and Kenya. BMC Med Ethics. 2014;15(76). doi:10.1186/1472-6939-15-76.
22. Mungwira RG, Nyangulu W, Misirri I, Iphani S, Ngumbula RL, Chirombo CM, Masiye F, Mfutso-Bengo J. Is it ethical to prevent secondary use of stored biological samples and data derived from consenting research participants? The case of Malawi. BMC Med Ethics. 2015;16(1). doi:10.1186/s12910-015-0077-x.
23. Barchi F, Mathagala K, Jones N, Kebaabetswe PM, Merz JF. The keeping is the problem": A qualitative study of IRB-member perspectives in Botswana on the collection, use, and storage of human biological samples for research. BMC Med Ethics. 2015;16(54). doi:10.1186/s12910-015-0047-3.
24. CEPI. 1st biological standards and assays workshop report. In: Coalition for Epidemic Preparedness Innovations. 2017 [accessed 2019 Apr 03]. https://cepi.net/research_dev/vaccine-science/.
25. Lippi G, Simundic AM, Rodriguez-Manas L, Bossuyt P, Banfi G. Standardizing in vitro diagnostics tests in clinical trials: a call for action. Ann Transl Med. 2016;4(181). doi:10.21037/atm.2016.04.10.
26. Giavarina D, Lippi G. Blood venous sample collection: recommendations overview and a checklist to improve quality. Clin Biochem. 2017;50(568–573). doi:10.1016/j.clinbiochem.2017.02.021.

27. Marko-Varga G, Baker MS, Boja ES, Rodriguez H, Fehniger TE. Biorepository regulatory frameworks: building parallel resources that both promote scientific investigation and protect human subjects. J Proteome Res. 2014;13(3319–3324). doi:10.1021/pr500475q.

28. Smith JF, Kowalski R, Esser MT, Brown MJ, Bryan JT. Evolution of type-specific immunoassays to evaluate the functional immune response to Gardasil: a vaccine for human papillomavirus types 16, 18, 6 and 11. Hum Vaccin. 2008;4:134–42. doi:10.4161/hv.4.2.5261.

29. Nyan DC, Swinson KL. A novel multiplex isothermal amplification method for rapid detection and identification of viruses. Sci Rep. 2015;5(17925). doi:10.1038/srep17925.

30. Ghodbane M, Stucky EC, Maguire TJ, Schloss RS, Shirehei DI, Zahn JD, Yarmush ML. Development and validation of a microfluidic immunoassay capable of multiplexing parallel samples in microliter volumes. Lab Chip. 2015;15(3211–3221). doi:10.1039/c5lc00398a.

31. Ronnberg B, Gustafsson A, Vapalahti O, Emmerich P, Lundkvist Å, Schmidt-Chanasit J, Blomberg J. Compensating for losses in patients. EBioMedicine. 2014;10(05.022).

32. Taylor CT, Mackay I, McMahon J, Wheatey S, Moore P, Finger M, Hewiston G, Moore F. Detection of Specific ZIKV IgM in travelers using a multiplexed flavivirus microsphere immunoassay. Viruses. 2018;10. doi:10.3390/v10050253.

33. Bryan JT, Buckland B, Hammond J, Jansen KS. Prevention of Middle East respiratory syndrome coronavirus infection. Viral Immunol. 2015;29(3221–2262).

34. Cunningham AL, Wei M, Sun G, Wang X, Li M, Lin Z, Li Z, Li Y, Fang M, Zhang J, et al. Vaccine development: from concept to clinical testing. Vaccine. 2016;34(6655–6664). doi:10.1016/j.vaccine.2016.10.016.

35. Bryan JT, Buckland B, Hammond J, Jansen KS. Evolution of cervical cancer: journey to develop the first human papillomavirus virus-like particle vaccine and the next generation vaccine. Curr Opin Chem Biol. 2016;32(34–47). doi:10.1016/j.cbpa.2016.03.001.

36. Cunningham AL, Wei M, Sun G, Wang X, Li M, Lin Z, Li Z, Li Y, Fang M, Zhang J, et al. Development of a human papillomavirus competitive luminescence immunoassay for 9 HPV types. Hum Vaccin Immunother. 2014;10(2168–2174). doi:10.4161/hv.29205.

37. Taylor CT, Mackay I, McMahon J, Wheatey S, Moore P, Finger M, Hewiston G, Moore F. Detection of Specific ZIKV IgM in travelers using a multiplexed flavivirus microsphere immunoassay. Viruses. 2018;10. doi:10.3390/v10050253.

38. Bryan JT, Buckland B, Hammond J, Jansen KS. Evolution of cervical cancer: journey to develop the first human papillomavirus virus-like particle vaccine and the next generation vaccine. Curr Opin Chem Biol. 2016;32(34–47). doi:10.1016/j.cbpa.2016.03.001.

39. Cunningham AL, Wei M, Sun G, Wang X, Li M, Lin Z, Li Z, Li Y, Fang M, Zhang J, et al. Development of a human papillomavirus competitive luminescence immunoassay for 9 HPV types. Hum Vaccin Immunother. 2014;10(2168–2174). doi:10.4161/hv.29205.

40. Bryan JT, Buckland B, Hammond J, Jansen KS. Prevention of Middle East respiratory syndrome coronavirus infection. Viral Immunol. 2015;29(3221–2262).

41. Cunningham AL, Wei M, Sun G, Wang X, Li M, Lin Z, Li Z, Li Y, Fang M, Zhang J, et al. Vaccine development: from concept to clinical testing. Vaccine. 2016;34(6655–6664). doi:10.1016/j.vaccine.2016.10.016.

42. Ciura A, Prat I, Nuebling CM, Wood D, Moussey F. Update on Zika diagnostic tests and WHO’s related activities. PLoS Negl Trop Dis. 2017;11(0005269). doi:10.1371/journal.pntd.0005269.

43. Alhethel A, Altalhi H, Albarqar A, Shakoor Z, Mohamed D, El-Hammami M, Som钜 K, Barry M, Bakreheah M, Nassar M. Assessing the detection of middle east respiratory syndrome coronavirus IgG in suspected and proven cases of middle east respiratory syndrome coronavirus infection. Viral Immunol. 2017;30 (649–653). doi:10.1089/vim.2017.0091.

44. Balmaseda A, Zambrana JV, Collado D, Garcia N, Saborio S, Elizondo D, Mercado JC, Gonzalez K, Cerpas C, Nunez A, et al. Comparison of four serological methods and two reverse transcription-PCR assays for diagnosis and surveillance of Zika virus infection. J Clin Microbiol. 2018;56. doi:10.1128/JCM.01785-17.

45. Wilder-Smith A, Vannice K, Durbin A, Hombach J, Thomas SJ, Thevarjan I, Simmons CP. Zika vaccines and therapeutics: landscape analysis and challenges ahead. BMC Med. 2018;16(84). doi:10.1186/s12916-018-1067-x.

46. FDA. Current emergency use authorizations. [accessed 2019 Apr 03]. https://www.fda.gov/EmergencyPreparedness/Counterterrorism/MedicalCountermeasures/UCM494615.htm#current.

47. FDA. Zika emergency use authorizations. [accessed 2018 Sep 06]. https://www.fda.gov/medicaldevices/safety/emergencysituations/ucm161496.html#zika.

48. WHO. World Health Organization emergency use and listings procedures. [accessed 2018 Sep 06]. http://www.who.int/medicines/news/public_consult_med_prods/en/.

49. FDA Zika virus diagnostic development. [accessed 2018 Sep 21]. https://www.fda.gov/EmergencyPreparedness/Counterterrorism/MedicalCountermeasures/UCM494615.htm#pport.

50. Park SW, Perera RA, Choe PG, Lau EH, Choi SJ, Chun JY, Oh HS, Song KH, Bang JH, Kim ES, et al. Comparison of serological assays in human Middle East respiratory syndrome (MERS)-coronavirus infection. Euro Surveill. 2015;20. doi:10.2807/1560-7917.ES.2015.20.4.30042.

51. Corman VM, Rasche A, Baronti C, Aldabbagh S, Cesar D, Reusken CB, Pas SD, Goorhuis A, Schinkel J, Molenkamp R, et al. Assay optimization for molecular detection of Zikv virus. Bull World Health Organ. 2016;94(880–892). doi:10.2471/BLT.16.175950.

52. Faye O, Faye O, Diallo D, Diallo M, Weidmann M, Sall AA. Quantitative real-time PCR detection of Zika virus and evaluation with field-caught Mosquitoes. Virol J. 2013;10(311). doi:10.1186/1743-422X-10-311.

53. Huzly D, Hanselmann I, Schmidt-Chanasit J, Panning M. High specificity of a novel Zika virus ELISA in European patients after exposure to different flaviviruses. Euro Surveill. 2016;21. doi:10.2807/1560-7917.ES.2016.21.16.30203.

54. L’Huillier AG, Lombok E, Tang E, Perusini S, Eshaghi A, Nagra S, Frantz C, Olsha R, Kristjanson E, Dimitrova K, et al. Evaluation of altona diagnostics realstar zika virus reverse transcription-PCR test kit for zika virus PCR testing. J Clin Microbiol. 2017;55(1576–1584). doi:10.1128/JCM.02153-16.

55. Steinhagen K, Probst C, Radzimski C, Schmidt-Chanasit J, Emmerich P, van Esbroeck M, Schinkel J, Grobousk MP, Goorhuis A, Warnecke JM, et al. Serodiagnosis of Zika virus (ZIKV) infections by a novel NS1-based ELISA devoid of cross-reactivity with dengue virus antibodies: a multicohort study of assay performance, 2015 to 2016. Euro Surveill. 2016;21. doi:10.2807/1560-7917.ES.2016.21.50.30426.

56. Waggoner JJ, Gresh L, Mohamed-Hadley A, Ballesteros G, Davilla MJ, Tellez Y, Sahoo MK, Balmaseda A, Harris E, Pinsky BA. Single-reaction multiplex reverse transcription PCR for detection of zika, chikungunya, and dengue viruses. Emerg Infect Dis. 2016;22(1295–1297). doi:10.3201/eid2207.160326.

57. FDA zika EUA Tablet molecular assay performance characteristics. [accessed 2018 Sep 21]. https://www.fda.gov/downloads/medicaldevices/safety/emergencysituations/UCM606289.pdf.
58. FDA zika eu table 2 summary molecular assay characteristics. [accessed 2018 Sep 06]. https://www.fda.gov/downloads/MedicalDevices/Safety/EmergencySituations/UCM606290.pdf.
59. CDC zika testing guidance for healthcare providers. [accessed 2018 Sep 21]. https://www.cdc.gov/zika/hc-providers/testing-guidance.html.
60. CDC U Interpretation of Nucleic Acid and Immunoassay test results for suspected Zika Infection. 2017 [accessed 2018 Sep 06]. https://www.cdc.gov/zika/laboratories/lab-guidance.html#table1.
61. Plotkin SA. Vaccines for epidemic infections and the role of CEPI. Hum Vaccin Immunother. 2017;13(2755–2762). doi:10.1080/21645515.2017.1306615.
62. Wong G, Qiu X. Funding vaccines for emerging infectious diseases. Hum Vaccin Immunother. 2018;14(1760–1762). doi:10.1080/21645515.2017.1412024.
63. Burd EM. Validation of laboratory-developed molecular assays for infectious diseases. Clin Microbiol Rev. 2010;23(550–576). doi:10.1128/CMR.00074-09.
64. Charrel RN, Leparc-Goffart I, Pas S, de Lamballerie X, Koopmans M, Reusken. C. Background review for diagnostic test development for Zika virus infection. Bull World Health Organ. 2016;94:574–584D. doi:10.2471/BLT.16.171207.
65. Yamaoka Y, Matsuyama S, Fukushima S, Matsunaga S, Matsushima Y, Kuroyama H, Kimura H, Takeda M, Chimuro T, Ryo A. Development of monoclonal antibody and diagnostic test for middle east respiratory syndrome coronavirus using cell-free synthesized nucleocapsid antigen. Front Microbiol. 2016;7(509). doi:10.3389/fmicb.2016.00509.
66. Cabral-Castro MJ, Cavalcanti MG, Peralta RHS, Peralta JM. Molecular and serological techniques to detect co-circulation of DENV, ZIKV and CHIKV in suspected dengue-like syndrome patients. J Clin Virol. 2016;82(108–111). doi:10.1016/j.jcv.2016.07.017.
67. Barbe B, Verdonck K, El-Safi S, Khanal B, Teav S, Lilo Kalo JR, Ravinneto R, Chappuis F, Boelaert M, Jacobs J. Rapid diagnostic tests for neglected infectious diseases: case study highlights need for customer awareness and postmarket surveillance. PLoS Negl Trop Dis. 2016;10(e0004655). doi:10.1371/journal.pntd.0004655.
68. Waggoner JJ, Pinsky BA. Zika Virus: diagnostics for an Emerging Pandemic Threat. J Clin Microbiol. 2016;54(860–867). doi:10.1128/JCM.00279-16.
69. Saraswathy Subramaniam TS, Thayan R, Yusof MA, Suppiah J, Tg Abd Rashid TR, Zawawi ZM, Mat Rahim NA, Kassim F, Zain RM, Saat Z. Sharing experiences from a reference laboratory in the public health response for Ebola viral disease, MERS-CoV and H7N9 influenza virus investigations. Asian Pac J Trop Med. 2016;9(201–203). doi:10.1016/j.aptm.2016.01.016.
70. Hashemzadeh MS, Rasouli R, Zahraei B, Izadi M, Tat M, Saadat SH, Najjaral M, Khansari Nejad B, Dorostkar R. Development of dual taqman based one-step rRT-PCR assay panel for rapid and accurate diagnostic test of MERS-CoV: A novel human coronavirus, ahead of hajj pilgrimage. Iran Red Crescent Med J. 2016;18(e23874). doi:10.5812/ircmj.23874.
71. Singh RK, Dhami K, Kartik K, Tiwari R, Khandia R, Munjal A, Iqbal HMN, Malik YS, Bueno-Mari R. Advances in diagnosis, surveillance, and monitoring of zika virus: an update. Front Microbiol. 2017;8(2677). doi:10.3389/fmicb.2017.02677.
72. Uyeki TM, Erlandson KJ, Korch G, O’Hara M, Wathen M, Hu-Primmer J, Hojvat S, Stemmy EJ, Donabedian A. Development of medical countermeasures to middle east respiratory syndrome coronavirus. Emerg Infect Dis. 2016;22. doi:10.3201/eid2207.160022.
73. Perkins MD, Dye C, Balasegaram M, Bréchot C, Mombouli J-V, Röttingen J-A, Tanner M, Boehme CC. Diagnostic preparedness for infectious disease outbreaks. The Lancet. 2017;390(2211–2214). doi:10.1016/s0140-6736(17)31224-2.